Rubric Capital Management (New York)’s Trevi Therapeutics TRVI Stock Holding History

Rubric Capital Management (New York)’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.7M	Sell	2,504,513 -1,207,860	-33%	-$17.6M	0.43%	59
2026 Q1	$44.3M	Sell	3,712,373 -54,376	-1%	-$609K	0.47%	45
2025 Q4	$47.2M	Sell	3,766,749 -4,765,111	-56%	-$55.1M	0.56%	47
2025 Q3	$78.1M	Hold	8,531,860	–	–	0.88%	30
2025 Q2	$46.7M	Buy	8,531,860 +3,993,325	+88%	+$24.8M	0.71%	36
2025 Q1	$28.5M	Buy	4,538,535 +333,406	+8%	+$1.59M	0.51%	40
2024 Q4	$17.3M	Sell	4,205,129 -821,802	-16%	-$2.63M	0.22%	50
2024 Q3	$16.8M	Hold	5,026,931	–	–	0.27%	48
2024 Q2	$15M	Sell	5,026,931 -537,192	-10%	-$1.49M	0.39%	50
2024 Q1	$19.2M	Sell	5,564,123 -120,297	-2%	-$268K	0.57%	48
2023 Q4	$7.62M	Hold	5,684,420	–	–	0.16%	48
2023 Q3	$12.4M	Hold	5,684,420	–	–	0.46%	47
2023 Q2	$13.6M	Hold	5,684,420	–	–	0.58%	42
2023 Q1	$10.5M	Hold	5,684,420	–	–	0.27%	54
2022 Q4	$11M	Hold	5,684,420	–	–	0.48%	53
2022 Q3	$8.75M	Buy	5,684,420 +3,906,000	+220%	+$12.8M	0.44%	49
2022 Q2	$5M	Buy	+1,778,420	New	+$4.37M	0.26%	61

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Rubric Capital Management (New York)'s TRVI Position: Q2 2026 in Review

Rubric Capital Management (New York) reduced its Trevi Therapeutics (TRVI) stake by 33% in Q2 2026, selling an estimated $17.6M and leaving 2,504,513 shares worth $46.7M. The position accounts for 0.43% of the portfolio, ranked #59.

Rubric Capital Management (New York) first reported a position in TRVI in Q2 2022 and has held it in 17 quarters since. The position peaked at $78.1M in Q3 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

Rubric Capital Management (New York) held 2,504,513 shares of Trevi Therapeutics worth $46.7M as of Q2 2026.
Rubric Capital Management (New York) sold 1,207,860 Trevi Therapeutics shares in Q2 2026, an estimated $17.6M.
Trevi Therapeutics made up 0.43% of Rubric Capital Management (New York)'s portfolio in Q2 2026, its #59 holding.
Rubric Capital Management (New York) first reported a position in Trevi Therapeutics in Q2 2022 and has held it in 17 quarters since.
Rubric Capital Management (New York)'s Trevi Therapeutics position peaked at $78.1M in Q3 2025.
218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.